The FDA has approved Treanda, an injectable drug from Cephalon, for use in patients with chronic lymphocytic leukemia. A study showed that 59% of patients responded to the drug and 8% experienced complete remission of the disease, the company said. Treanda is also under review for the treatment of indolent B-cell non-Hodgkin's lymphoma, a type of blood cancer.

Related Summaries